Kiniksa Pharmaceuticals International, plc (KNSA) Stock Score, Valuation & Financial Research
Kiniksa Pharmaceuticals International, plc is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 43/100.
Quick answer for KNSA
Kiniksa Pharmaceuticals International, plc currently has a Wall Street Score of 43/100. The stored market price is $76.27. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Kiniksa Pharmaceuticals International, plc does
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the Unite
KNSA financial snapshot
- Wall Street Score:
- 43/100
- Current price:
- $76.27
- Market capitalization:
- $5.81B
- Revenue:
- $754.0M
- Net income:
- $73.1M
- Free cash flow:
- $25.4M
- Cash:
- $190.0M
- Total debt:
- $9.0M
- EPS:
- 0.80
- P/E ratio:
- 95.3x
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $25.4M, showing positive cash generation.
- The balance sheet shows $190.0M of cash versus $9.0M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KNSA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.